After its long-time chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has tapped Katie Szyman for the role, who served as head of Edwards' critical ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. | Neomorph is ...

Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...

An FDA advisory committee may have ruled in elamipretide’s favor back in October, but it looks like Stealth BioTherapeutics ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Exicure was an expiring company with no money or active pipeline. | A couple of months ago, Exicure was an expiring company ...

Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...

Robert F. Kennedy Jr. will be pulling his investments from two biotechs if he is confirmed to lead the U.S. Department of ...

Following last year’s launches of several all-in-one CRO offerings, Lindus Health is starting 2025 strong by closing a $55 ...

Beta Bionics has set the terms for its plan to go public, with a goal of raising at least $114 million to support its ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...